{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:31:50Z","timestamp":1772843510849,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,3]]},"DOI":"10.7759\/cureus.75062","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T02:57:47Z","timestamp":1733281067000},"source":"Crossref","is-referenced-by-count":3,"title":["Evolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Alan D","family":"Kaye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph  P","family":"Tassin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William c","family":"Upshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandni  R","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison M","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline  R","family":"Burroughs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin Nicole","family":"Bembenick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chizoba  N","family":"Mosieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam M","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37795","article-title":"Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004","volume":"65","author":"Feldman CH","year":"2013","unstructured":"Feldman CH, Hiraki LT, Liu J, et al.. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum. 2013, 65:753-63. 10.1002\/art.37795","journal-title":"Arthritis Rheum"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.191187","article-title":"Healthcare utilization and costs of systemic lupus erythematosus by disease severity in the United States","volume":"48","author":"Murimi-Worstell IB","year":"2021","unstructured":"Murimi-Worstell IB, Lin DH, Kan H, et al.. Healthcare utilization and costs of systemic lupus erythematosus by disease severity in the United States. J Rheumatol. 2021, 48:385-93. 10.3899\/jrheum.191187","journal-title":"J Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350310","article-title":"A revised estimate of twin concordance in systemic lupus erythematosus","volume":"35","author":"Deapen D","year":"1992","unstructured":"Deapen D, Escalante A, Weinrib L, et al.. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992, 35:311-8. 10.1002\/art.1780350310","journal-title":"Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0065-2776(01)76021-x","article-title":"Systemic lupus erythematosus, complement deficiency, and apoptosis","volume":"76","author":"Pickering MC","year":"2000","unstructured":"Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol. 2000, 76:227-324. 10.1016\/s0065-2776(01)76021-x","journal-title":"Adv Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2003.09.006","article-title":"The genetics of human systemic lupus erythematosus","volume":"24","author":"Tsao BP","year":"2003","unstructured":"Tsao BP. The genetics of human systemic lupus erythematosus. Trends Immunol. 2003, 24:595-602. 10.1016\/j.it.2003.09.006","journal-title":"Trends Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/08916930701763710","article-title":"Fc receptor genes and the systemic lupus erythematosus diathesis","volume":"40","author":"Brown EE","year":"2007","unstructured":"Brown EE, Edberg JC, Kimberly RP. Fc receptor genes and the systemic lupus erythematosus diathesis. Autoimmunity. 2007, 40:567-81. 10.1080\/08916930701763710","journal-title":"Autoimmunity"},{"key":"ref7","article-title":"Systemic lupus erythematosus","author":"Justiz Vaillant AA","year":"2024","unstructured":"Justiz Vaillant AA, Goyal A, Varacallo M. Systemic lupus erythematosus. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.56.7.481","article-title":"Pathogenesis of systemic lupus erythematosus","volume":"56","author":"Mok CC","year":"2003","unstructured":"Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003, 56:481-90. 10.1136\/jcp.56.7.481","journal-title":"J Clin Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(95)90114-0","article-title":"Prevention of relapses in systemic lupus erythematosus","volume":"24","author":"Bootsma H","year":"1995","unstructured":"Bootsma H, Spronk P, Derksen R, et al.. Prevention of relapses in systemic lupus erythematosus. Lancet . 1995, 24:1595-9. 10.1016\/s0140-6736(95)90114-0","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.147.1.117","article-title":"Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis","volume":"147","author":"Linker-Israeli M","year":"1991","unstructured":"Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol. 1991, 147:117-23.","journal-title":"J Immunol"},{"key":"ref11","article-title":"Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus","volume":"4","author":"Llorente L","year":"1993","unstructured":"Llorente L, Richaud-Patin Y, Wijdenes J, et al.. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw. 1993, 4:421-7.","journal-title":"Eur Cytokine Netw"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199805)41:5<838::AID-ART10>3.0.CO;2-S","article-title":"Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus","volume":"41","author":"Horwitz DA","year":"1998","unstructured":"Horwitz DA, Gray JD, Behrendsen SC, et al.. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum. 1998, 41:838-44. 10.1002\/1529-0131(199805)41:5&lt;838::AID-ART10&gt;3.0.CO;2-S","journal-title":"Arthritis Rheum"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5606\/ArchRheumatol.2017.6127","article-title":"A systematic review and meta-analysis of prevalence of biopsy-proven lupus nephritis","volume":"33","author":"Wang H","year":"2018","unstructured":"Wang H, Ren YL, Chang J, Gu L, Sun LY. A systematic review and meta-analysis of prevalence of biopsy-proven lupus nephritis. Arch Rheumatol. 2018, 33:17-25. 10.5606\/ArchRheumatol.2017.6127","journal-title":"Arch Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040670","article-title":"Management of lupus nephritis","volume":"10","author":"Tamirou F","year":"2021","unstructured":"Tamirou F, Houssiau FA. Management of lupus nephritis. J Clin Med. 2021, 10:670. 10.3390\/jcm10040670","journal-title":"J Clin Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)","volume":"76","author":"van Vollenhoven R","year":"2017","unstructured":"van Vollenhoven R, Voskuyl A, Bertsias G, et al.. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017, 76:554-61. 10.1136\/annrheumdis-2016-209519","journal-title":"Ann Rheum Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05306-5","article-title":"Current treatment of systemic lupus erythematosus: a clinician's perspective","volume":"43","author":"Katarzyna PB","year":"2023","unstructured":"Katarzyna PB, Wiktor S, Ewa D, Piotr L. Current treatment of systemic lupus erythematosus: a clinician's perspective. Rheumatol Int. 2023, 43:1395-407. 10.1007\/s00296-023-05306-5","journal-title":"Rheumatol Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12113639","article-title":"Steroids in lupus: enemies or allies","volume":"12","author":"Enr\u00edquez-Merayo E","year":"2023","unstructured":"Enr\u00edquez-Merayo E, Cuadrado MJ. Steroids in lupus: enemies or allies. J Clin Med. 2023, 12:3639. 10.3390\/jcm12113639","journal-title":"J Clin Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2020.022","article-title":"Treatment of systemic lupus erythematosus","volume":"43","author":"McKeon KP","year":"2020","unstructured":"McKeon KP, Jiang SH. Treatment of systemic lupus erythematosus. Aust Prescr. 2020, 43:85-90. 10.18773\/austprescr.2020.022","journal-title":"Aust Prescr"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211073001","article-title":"Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge","volume":"14","author":"Dima A","year":"2022","unstructured":"Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis. 2022, 14:1759720X211073001. 10.1177\/1759720X211073001","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/24741264221097806","article-title":"Compliance with hydroxychloroquine screening guidelines at a large academic medical center","volume":"6","author":"Islam YF","year":"2022","unstructured":"Islam YF, Stroman WR, Steigleman WA. Compliance with hydroxychloroquine screening guidelines at a large academic medical center. J Vitreoretin Dis. 2022, 6:271-7. 10.1177\/24741264221097806","journal-title":"J Vitreoretin Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/09629359890910","article-title":"Glucocorticoids: mechanisms of action and anti-inflammatory potential in asthma","volume":"7","author":"van der Velden VH","year":"1998","unstructured":"van der Velden VH. Glucocorticoids: mechanisms of action and anti-inflammatory potential in asthma. Mediators Inflamm. 1998, 7:229-37. 10.1080\/09629359890910","journal-title":"Mediators Inflamm"},{"key":"ref22","article-title":"Corticosteroid adverse effects","author":"Yasir M","year":"2024","unstructured":"Yasir M, Goyal A, Sonthalia S. Corticosteroid adverse effects. StatPearls [Internet], StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref23","article-title":"Cyclophosphamide","author":"Ogino MH","year":"2024","unstructured":"Ogino MH, Tadi P. Cyclophosphamide. StatPearls [Internet], StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref24","unstructured":"Mycophenolate. (2024). Accessed.  September 21, 2024: https:\/\/medlineplus.gov\/druginfo\/meds\/a601081.html."},{"key":"ref25","article-title":"Methotrexate","author":"Hanoodi M","year":"2024","unstructured":"Hanoodi M, Mittal M. Methotrexate. StatPearls [Internet], StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref26","unstructured":"Immunosuppressive treatment for proliferative lupus nephritis. (2024). Accessed. September 21, 2024: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6513226\/."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.058412","article-title":"The BLyS\/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity","volume":"65 Suppl 3","author":"Cancro MP","year":"2006","unstructured":"Cancro MP. The BLyS\/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis. 2006, 65 Suppl 3:iii34-6. 10.1136\/ard.2006.058412","journal-title":"Ann Rheum Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay F","year":"1999","unstructured":"Mackay F, Woodcock SA, Lawton P, et al.. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999, 190:1697-710. 10.1084\/jem.190.11.1697","journal-title":"J Exp Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.190107","article-title":"Belimumab in systemic lupus erythematosus","volume":"61","author":"Srivastava A","year":"2016","unstructured":"Srivastava A. Belimumab in systemic lupus erythematosus. Indian J Dermatol. 2016, 61:550-3. 10.4103\/0019-5154.190107","journal-title":"Indian J Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"26","author":"Navarra SV","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, et al.. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2011, 26:721-31. 10.1016\/S0140-6736(10)61354-2","journal-title":"Lancet Lond Engl"},{"key":"ref31","unstructured":"Why BENLYSTA? | BENLYSTA (belimumab). Accessed. October 15, 2024: https:\/\/www.benlysta.com\/about-benlysta-for-lupus\/why-benlysta\/."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie R","year":"2017","unstructured":"Furie R, Khamashta M, Merrill JT, et al.. Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017, 69:376-86. 10.1002\/art.39962","journal-title":"Arthritis Rheumatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2012.03.005","article-title":"Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha","volume":"143","author":"Lichtman EI","year":"2012","unstructured":"Lichtman EI, Helfgott SM, Kriegel MA. Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha. Clin Immunol. 2012, 143:210-21. 10.1016\/j.clim.2012.03.005","journal-title":"Clin Immunol"},{"key":"ref34","unstructured":"Anifrolumab phase III trial meets primary endpoint in systemic lupus erythematosus . (2019). Accessed. September 22, 2024: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/anifrolumab-phase-iii-trial-meets-primary-endpoint-in-sy...."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000761","article-title":"Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials","volume":"10","author":"Bruce IN","year":"2023","unstructured":"Bruce IN, van Vollenhoven RF, Psachoulia K, Lindholm C, Maho E, Tummala R. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials. Lupus Sci Med. 2023, 10:e000761. 10.1136\/lupus-2022-000761","journal-title":"Lupus Sci Med"},{"key":"ref36","unstructured":"Drug trials snapshots. Saphnelo. ( 2023). Accessed: October 15, 2024: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-saphnelo."},{"key":"ref37","unstructured":"What you need to know about SaphneloTM. (2024). Accessed. September 22, 2024: https:\/\/www.lupus.org\/resources\/saphnelo-what-you-need-to-know."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie RA","year":"2022","unstructured":"Furie RA, van Vollenhoven RF, Kalunian K, et al.. Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus. N Engl J Med. 2022, 387:894-904. 10.1056\/NEJMoa2118025","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201404719","article-title":"Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms","volume":"7","author":"Pellerin A","year":"2015","unstructured":"Pellerin A, Otero K, Czerkowicz JM, et al.. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms. EMBO Mol Med. 2015, 7:464-76. 10.15252\/emmm.201404719","journal-title":"EMBO Mol Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.10.014","article-title":"Type I interferon in the pathogenesis of systemic lupus erythematosus","volume":"67","author":"Postal M","year":"2020","unstructured":"Postal M, Vivaldo JF, Fernandez-Ruiz R, Paredes JL, Appenzeller S, Niewold TB. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol. 2020, 67:87-94. 10.1016\/j.coi.2020.10.014","journal-title":"Curr Opin Immunol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.370","article-title":"Cenerimod, a novel selective S1P(1) receptor modulator with unique signaling properties","volume":"5","author":"Piali L","year":"2017","unstructured":"Piali L, Birker-Robaczewska M, Lescop C, et al.. Cenerimod, a novel selective S1P(1) receptor modulator with unique signaling properties. Pharmacol Res Perspect. 2017, 5:10.1002\/prp2.370","journal-title":"Pharmacol Res Perspect"},{"key":"ref42","unstructured":"Preclinical to clinical translation of cenerimod, a novel S1P1 receptor modulator, in systemic lupus erythematosus. (2024). Accessed. September 23, 2024: https:\/\/pubmed.ncbi.nlm.nih.gov\/32917831\/."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000354","article-title":"First use of cenerimod, a selective S1P(1) receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study","volume":"6","author":"Hermann V","year":"2019","unstructured":"Hermann V, Batalov A, Smakotina S, Juif PE, Cornelisse P. First use of cenerimod, a selective S1P(1) receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lupus Sci Med. 2019, 6:e000354. 10.1136\/lupus-2019-000354","journal-title":"Lupus Sci Med"},{"key":"ref44","unstructured":"CAR T cells. engineering immune cells to treat cancer - NCI. (2013). Accessed: October 15, 2024: https:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/art.40396","article-title":"Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us","volume":"70","author":"Karrar S","year":"2018","unstructured":"Karrar S, Cunninghame Graham DS. Abnormal B cell development in systemic lupus erythematosus: what the genetics tell us. Arthritis Rheumatol. 2018, 70:496-507. 10.1002\/art.40396","journal-title":"Arthritis Rheumatol"},{"key":"ref46","article-title":"Immunophenotyping","author":"Herold NC","year":"2024","unstructured":"Herold NC, Mitra P. Immunophenotyping. StatPearls [Internet], StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen A","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, et al.. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022, 28:2124-32. 10.1038\/s41591-022-02017-5","journal-title":"Nat Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6117","article-title":"First-in-human study of the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of DS-7011a, an anti-TLR7 antagonistic monoclonal antibody for the treatment of systemic lupus erythematosus","author":"Senaldi G","year":"2024","unstructured":"Senaldi G, Mohan A, Zhang L, et al.. First-in-human study of the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of DS-7011a, an anti-TLR7 antagonistic monoclonal antibody for the treatment of systemic lupus erythematosus. J Clin Pharmacol. 2024, 10.1002\/jcph.6117","journal-title":"J Clin Pharmacol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1177\/09612033241287594","article-title":"JAK inhibitors in systemic lupus erythematosus: translating pathogenesis into therapy","volume":"33","author":"Ceobanu G","year":"2024","unstructured":"Ceobanu G, Edwards CJ. JAK inhibitors in systemic lupus erythematosus: translating pathogenesis into therapy. Lupus. 2024, 33:1403-15. 10.1177\/09612033241287594","journal-title":"Lupus"},{"key":"ref50","unstructured":"A feasibility randomised placebo-controlled trial with objective outcome measures to evaluate the efficacy of biosimilar rituximab in musculoskeletal and mucocutaneous systemic lupus erythematosus. (2019). Accessed. November 13, 2024: https:\/\/clinicaltrials.gov\/study\/NCT03054259."},{"key":"ref51","unstructured":"Pilot study of rituximab therapy for systemic lupus erythematosus (SLE) and vasculitis resistant to conventional therapy. (2006). Accessed. November 13, 2024: https:\/\/clinicaltrials.gov\/study\/NCT00293072."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/310904-evolving-treatment-strategies-for-systemic-lupus-erythematosus-in-clinical-practice-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T02:57:56Z","timestamp":1733281076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/310904-evolving-treatment-strategies-for-systemic-lupus-erythematosus-in-clinical-practice-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":51,"URL":"https:\/\/doi.org\/10.7759\/cureus.75062","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,3]]}}}